FDA Clears Medtronic’s Affera Prism-2 Mapping Software

Medtronic said 30 September 2026 that it won FDA 510(k) clearance and a CE Mark for Affera Prism-2, the newest mapping software for its cardiac-ablation platform, and a CE Mark — separately, and so far only in Europe — for the PulseSelect ProxBox Adapter with Proximity Indicator software. The company's own release is the fullest public account of either milestone; independent trade coverage of this specific announcement has not yet surfaced.

What Prism-2 adds

Affera Prism-2 is software layered onto Medtronic's existing Affera mapping-and-ablation platform, used with the Sphere-9 catheter to treat atrial fibrillation and atrial flutter. Medtronic's announcement describes two new capabilities: Beat Matching, which compares heartbeats during a mapping procedure to help a physician flag signals that look abnormal, and Pace Tagging, which marks the locations where pacing occurred and assigns a score and color to the paced-beat morphology at each site. Both are software-level additions intended to speed up steps inside an already-running ablation workflow rather than new hardware. “Innovation in mapping software is essential to realizing the full potential of cardiac ablation technologies,” said Khaldoun Tarakji, MD, MPH, vice president and chief medical officer of cardiac ablation solutions at Medtronic, in the announcement. Rebecca Seidel, senior vice president and president of Medtronic's electrophysiology therapies business, added: “Software excellence is a priority across our electrophysiology business and is central to the integrated experience physicians expect.” Medtronic's release did not give a US commercial availability date for Prism-2 following the clearance.

One clearance, two CE Marks — not three identical wins

Medtronic's own headline refers to “regulatory milestones,” plural, and the two products inside that phrase cleared different bars. Prism-2 Mapping Software is where the FDA 510(k) clearance sits, alongside its own CE Mark. The PulseSelect ProxBox Adapter with Proximity Indicator software — a separate accessory for Medtronic's PulseSelect pulsed-field ablation system, which gives physicians impedance-based feedback on catheter proximity to tissue before energy delivery — received only a CE Mark in this announcement. Nothing in Medtronic's release states that ProxBox has FDA clearance, a pending FDA submission, or any other US regulatory status; Regulatory News found no source stating otherwise. RA teams reading the headline alone risk conflating three separate regulatory outcomes into one. A further gap: FDA's public device-classification records show an “Affera Integrated Mapping System” 510(k), K262005, with a decision date of 21 August 2026 — roughly six weeks before Medtronic's announcement, which is a plausible but unconfirmed lag. Medtronic's release does not cite a 510(k) number, and no public source ties K262005 to Prism-2 by name rather than to the broader Affera system. Separately, a hospital in Dublin, Ireland said in December 2025 that it was first in the world to use Prism-2 in a live case — which suggests a version of the software was already in European clinical use well before this announcement. Medtronic's release does not say whether the 30 September CE Mark is Prism-2's first European authorization or an update to an already CE-marked earlier version.

The competitive backdrop

Affera and PulseSelect sit on opposite sides of Medtronic's two-pronged approach to atrial-fibrillation ablation: Affera pairs high-density mapping with a catheter, Sphere-9, capable of both radiofrequency and pulsed-field energy, while PulseSelect is a dedicated pulsed-field ablation system that won FDA approval in December 2023 as the first such system cleared in the United States, with an indication covering both paroxysmal and persistent AFib. Boston Scientific's competing Farapulse pulsed-field system followed in January 2024, initially for paroxysmal AFib only. Mapping and ablation software has become a point of competitive differentiation as the energy-delivery side of the market matures. Separately, a 2026 field safety notice from French and Danish regulators covers discoloration found on the distal tip of a different Affera-family catheter, Sphere-360, in a small number of complaints with no reported patient harm; it does not involve Prism-2, Sphere-9, or PulseSelect, and RA teams tracking the Affera product line should not conflate the two.

Frequently asked questions

What did FDA actually clear?

FDA 510(k) clearance for Affera Prism-2 Mapping Software, part of the Affera cardiac-mapping and ablation platform, per Medtronic's 30 September 2026 announcement. Prism-2 also received a CE Mark. The PulseSelect ProxBox Adapter received a CE Mark only, with no stated US status.

What do Beat Matching and Pace Tagging do?

Beat Matching flags abnormal heartbeats during mapping; Pace Tagging marks and scores pacing locations during the procedure. No US launch date was given.

Is this the same product recalled earlier in 2026?

No. A 2026 field safety notice concerns the Sphere-360 catheter, a different Affera-family device, not Prism-2, Sphere-9, or PulseSelect.

Has this been independently verified?

Not yet. Secondary coverage found traces back to Medtronic's own release; no source confirms a specific 510(k) number for Prism-2 by name.